Telix Pharmaceuticals Limited (ASX:TLX) shares traded higher during the latest trading session, rising 2.17% to AUD 16.940 from the previous close of AUD 16.580. The biotechnology company's shares recorded positive price movement as investors monitored activity across the Pharmaceuticals, Biotechnology & Life Sciences sector.
ResMed Inc. (ASX:RMD) shares traded lower during the latest trading session, declining 2.82% to AUD 30.310 from the previous close of AUD 31.190. The healthcare equipment and services company recorded elevated trading activity as investors tracked movements across the healthcare sector.
Compumedics Ltd (ASX: CMP) came under selling pressure during the latest trading session, with its shares falling13.73%to close atAUD 0.22. The decline adds to the stock's longer-term performance, with shares now15.39% lower over the past year.
LTR Pharma Ltd (ASX: LTP) came under selling pressure during the latest trading session, with its shares falling12.28%to close atAUD 0.50. Despite the decline, the biotechnology company remains72.41% higher over the past 12 months, reflecting continued investor interest in its pharmaceutical development strategy.
NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) came under selling pressure during the latest trading session, with its shares declining11.43%to close atAUD 0.062. The latest move extends the company's longer-term weakness, with the stock now52.31% lowerthan it was a year ago.
LTR Pharma Ltd (ASX: LTP) came under selling pressure during the latest trading session, with its shares falling12.28%to close atAUD 0.50. Despite the decline, the biotechnology company remains72.41% higher over the past 12 months, reflecting continued investor interest in its pharmaceutical development strategy.
Pacific Edge Ltd (ASX: PEB) has attracted increased investor attention over the past year, with its shares gaining150.00%to close atAUD 0.245. The healthcare company's performance reflects continued market interest in molecular diagnostic technologies and developments surrounding its bladder cancer testing business.
For a company that develops and commercialises real, clinically validated molecular diagnostic products for hospital and pathology laboratory use, the scale of the decline raises uncomfortable questions: is the core commercial business genuinely failing, or has the market over-corrected following the post-pandemic normalisation of …
Ansell Ltd (ASX:ANN) traded lower during the afternoon session on 9 July 2026, with its shares easing 0.89% to AUD 31.60. While the decline reflected softer trading during the day, the company continues to maintain a positive longer-term performance, with the stock remaining 4.69% …
PharmX Technologies Ltd (ASX: PHX) attracted investor attention after its shares climbed9.52%toAUD 0.115. The latest gain adds to the company's longer-term performance, with the stock now27.78% higher over the past year.